top of page
Our Pipeline
GettyImages-1325076942.jpg

Our Pipeline

A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors.

Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.

 

With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.

Stage

NG-347

Three transgenes:

producing membrane bound CD80 and secreted MIP1α and IFNα

T-cell attraction

and activation

NG-796A

Three transgenes:

producing IL-12, IL-15 and a chemokine

T-cell and

NK Cell 

activation

NG-XXX

Novel transgene combinations

Variety of mechanisms targeted

Product

Transgene

Payload

Principal

Mechanism

NG-350A

Two transgenes:

producing a secreted CD40 agonist monoclonal antibody

NG-641

Four transgenes:

producing an anti-FAP bispecific plus cytokines/ chemokines

CD40 Agonism

Phase 1

Phase 2

Phase 3

Research

IND

Enabling

Commercial Rights

Anti-

Stromal

Akamis Therapeutics Virus V2.png
Psioxus 2 Transgene.png
Akamis Therapeutics Virus V2.png
Psioxus 4 Transgene.png
Akamis Therapeutics Virus V2.png
Akamis Therapeutics Virus V2.png
Akamis Therapeutics Virus V2.png
allwhite_dnastrand.png
Akamis Therapeutics Virus V2.png
Akamis Bio 2 Transgene.png

NG-348

Two transgenes:

producing membrane bound anti-CD3 scFv antibody and CD80

Immune cell recruitment & activation

bottom of page